Turner NC - Search Results

1

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC. Chopra N, et al. Among authors: turner nc. Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7. Nat Commun. 2020. PMID: 32471999 Free PMC article. Clinical Trial.

2

Hallmarks of 'BRCAness' in sporadic cancers.

Turner N, Tutt A, Ashworth A. Turner N, et al. Nat Rev Cancer. 2004 Oct;4(10):814-9. doi: 10.1038/nrc1457. Nat Rev Cancer. 2004. PMID: 15510162 Review.

3

Targeting the DNA repair defect of BRCA tumours.

Turner N, Tutt A, Ashworth A. Turner N, et al. Curr Opin Pharmacol. 2005 Aug;5(4):388-93. doi: 10.1016/j.coph.2005.03.006. Curr Opin Pharmacol. 2005. PMID: 15955736 Review.

4

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747

5

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: turner nc. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

6

BRCA1 dysfunction in sporadic basal-like breast cancer.

Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. Turner NC, et al. Oncogene. 2007 Mar 29;26(14):2126-32. doi: 10.1038/sj.onc.1210014. Epub 2006 Oct 2. Oncogene. 2007. PMID: 17016441

7

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Iorns E, et al. Among authors: turner nc. Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001. Cancer Cell. 2008. PMID: 18242510 Free article.

8

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. Turner NC, et al. EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3. EMBO J. 2008. PMID: 18388863 Free PMC article.

9

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. Lord CJ, et al. Among authors: turner nc. DNA Repair (Amst). 2008 Dec 1;7(12):2010-9. doi: 10.1016/j.dnarep.2008.08.014. Epub 2008 Oct 15. DNA Repair (Amst). 2008. PMID: 18832051

10

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS. Turner N, et al. Oncogene. 2010 Apr 8;29(14):2013-23. doi: 10.1038/onc.2009.489. Epub 2010 Jan 18. Oncogene. 2010. PMID: 20101236 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page